132 related articles for article (PubMed ID: 2505697)
1. Defective fibrinolysis in Behçet's syndrome: significance and possible mechanisms.
Aitchison R; Chu P; Cater DR; Harris RJ; Powell RJ
Ann Rheum Dis; 1989 Jul; 48(7):590-3. PubMed ID: 2505697
[TBL] [Abstract][Full Text] [Related]
2. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
3. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis.
Nguyen G; Horellou MH; Kruithof EK; Conard J; Samama MM
Blood; 1988 Aug; 72(2):601-5. PubMed ID: 3135860
[TBL] [Abstract][Full Text] [Related]
4. Coagulation and fibrinolytic activity in Behçet's disease.
Hampton KK; Chamberlain MA; Menon DK; Davies JA
Thromb Haemost; 1991 Sep; 66(3):292-4. PubMed ID: 1745999
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolytic activity and d-dimer levels in Behçet's syndrome.
Yurdakul S; Hekim N; Soysal T; Fresko I; Bavunoglu I; Ozbakir F; Tabak F; Melikoglu M; Hamuryudan V; Yazici H
Clin Exp Rheumatol; 2005; 23(4 Suppl 38):S53-8. PubMed ID: 16273765
[TBL] [Abstract][Full Text] [Related]
6. Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time.
Wright JG; Cooper P; Astedt B; Lecander I; Wilde JT; Preston FE; Greaves M
Br J Haematol; 1988 Jun; 69(2):253-8. PubMed ID: 3134043
[TBL] [Abstract][Full Text] [Related]
7. Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease.
Orem A; Değer O; Memiş O; Bahadir S; Ovali E; Cimşit G
Ann Rheum Dis; 1995 Sep; 54(9):726-9. PubMed ID: 7495343
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
10. Diurnal variation of the fibrinolytic system.
Grimaudo V; Hauert J; Bachmann F; Kruithof EK
Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
[TBL] [Abstract][Full Text] [Related]
11. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease.
Ozoran K; Dügün N; Gürler A; Tutkak H; Tokgöz G
Scand J Rheumatol; 1995; 24(6):376-82. PubMed ID: 8610223
[TBL] [Abstract][Full Text] [Related]
12. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.
Schleef RR; Higgins DL; Pillemer E; Levitt LJ
J Clin Invest; 1989 May; 83(5):1747-52. PubMed ID: 2496147
[TBL] [Abstract][Full Text] [Related]
13. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].
Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P
Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860
[TBL] [Abstract][Full Text] [Related]
14. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism.
Grimaudo V; Bachmann F; Hauert J; Christe MA; Kruithof EK
Thromb Haemost; 1992 Apr; 67(4):397-401. PubMed ID: 1631786
[TBL] [Abstract][Full Text] [Related]
15. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
[TBL] [Abstract][Full Text] [Related]
16. Release pattern of the vascular plasminogen activator and its inhibitor in human postvenous occlusion plasma as assessed by a spectrophotometric solid-phase fibrin-tPA activity assay.
Anglés-Cano E; Boutière B; Arnoux D; Masson C; Contant G; Benchimol P; Sampol J
Thromb Haemost; 1987 Oct; 58(3):843-9. PubMed ID: 3124285
[TBL] [Abstract][Full Text] [Related]
17. [Thromboembolic disease and anomalies of fibrinolysis].
Juhan-Vague I; Aillaud MF; Valadier J; Alessi MC; Serradimigni A
Ann Med Interne (Paris); 1986; 137(6):471-4. PubMed ID: 3101564
[TBL] [Abstract][Full Text] [Related]
18. Relationship between age and plasma t-PA, PA-inhibitor, and PA activity.
Hashimoto Y; Kobayashi A; Yamazaki N; Sugawara Y; Takada Y; Takada A
Thromb Res; 1987 Jun; 46(5):625-33. PubMed ID: 3114907
[TBL] [Abstract][Full Text] [Related]
19. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.
Juhan-Vague I; Valadier J; Alessi MC; Aillaud MF; Ansaldi J; Philip-Joet C; Holvoet P; Serradimigni A; Collen D
Thromb Haemost; 1987 Feb; 57(1):67-72. PubMed ID: 3109059
[TBL] [Abstract][Full Text] [Related]
20. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis.
Francis RB; McGehee WG; Feinstein DI
Thromb Haemost; 1988 Jun; 59(3):412-4. PubMed ID: 3142079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
